https://www.selleckchem.com/pr....oducts/retatrutide.h
Neuroblastoma is the most common pediatric extracranial tumor with varied prognoses, but the survival of treated refractory or relapsing patients remains poor. This analysis presents the outcomes of children with neuroblastoma undergoing MIBG therapy in Poland in 2006-2019. A retrospective cohort of 55 patients with refractory or relapsed neuroblastoma treated with I-131 MIBG in Poland in 2006-2019 was analyzed. The endpoints were overall survival (OS), event-free survival (EFS), cumulative incidence (CI) of second cancers and CI of
Like
Comment
Share
